Soleno Therapeutics ($SLNO) has been mentioned 24 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on August 21, 2025. Adam Feuerstein (@adamfeuerstein) accounts for 22 of these mentions, while Special Situation Investments (@ssi_invest) contributed 2 mentions. The biotech sector dominated discussion of this ticker. Most recent activity centers on a merger transaction: Neurocrine Biosciences announced an all-cash acquisition of $SLNO at $53.00 per share, valuing the deal at approximately $2.7 billion with an expected close in July 2026. A tender offer commenced on April 20, 2026, with expiration set for May 15, 2026, requiring majority tender approval and HSR clearance as closing conditions.